Global Achondroplasia Treatment Market, by Treatment Type (Growth Hormone therapy, surgery), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.
To know the latest insights, qualitative data, trends, quantitative data, and more related to Global Achondroplasia Treatment Market, visit :
https://www.meridianmarketconsultants.com/global-achondroplasia-treatment-market
As per the report, incidence of achondroplasia and launch of new therapies are the prime factor driving growth of achondroplasia treatment market. Achondroplasia is a rare genetic (inherited) bone disorder that occurs in one in 15,000 to 40,000 live births. Achondroplasia is the most common type of dwarfism, in which the child’s arms and legs are short in proportion to body length. Achondroplasia is an autosomal dominant disease. Approximately 80% of achondroplasia cases result from a new mutation in families. In the U.S. approximately 10,000 individuals are estimated to have achondroplasia. The prevalence of achondroplasia in the U.S. ranges from .36 to 0.60 per 10,000 live births. Achondroplasia accounts for 90% of dwarfism or disproportionate short stature. Worldwide prevalence of achondroplasia was found to be 1 in every 25,000–30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide. The condition affects men and women equally. Studies performed in Texas showed that fathers that >40 years of age had significantly increased rates of de novo achondroplasia among their offspring compared with younger fathers.
Contact Us:
Meridian Market Consultants (MMC)
13121, Louetta Road,
#440, Cypress, Texas 77429
United States
Tel: +1-(281)-619-8646